Indivior Pharmaceuticals (INDV) Long-Term Investments (2022 - 2026)

Indivior Pharmaceuticals' Long-Term Investments history runs 5 years deep, the most recent figure standing at $27.0 million for Q1 2026.

• On a quarterly basis, Long-Term Investments changed 0.0% year-over-year to $27.0 million in Q1 2026; TTM through Mar 2026 was $27.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $28.0 million, up 3.7% from the prior year.
• Long-Term Investments declined to $27.0 million in Q1 2026 per INDV's latest filing, from $28.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $98.0 million in Q4 2022 and bottomed at $27.0 million in Q4 2024.
• The 5-year median for Long-Term Investments is $27.5 million (2024), against an average of $37.9 million.
• Across the five-year window, Long-Term Investments plunged 58.16% in 2023 and gained 3.7% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $98.0 million in 2022, then plunged by 58.16% to $41.0 million in 2023, then tumbled by 34.15% to $27.0 million in 2024, then climbed by 3.7% to $28.0 million in 2025, then declined by 3.57% to $27.0 million in 2026.
• Per Business Quant, the three latest INDV Long-Term Investments figures stand at $27.0 million (Q1 2026), $28.0 million (Q4 2025), and $28.0 million (Q3 2025).